On Friday, August 22nd, the U. S. Drug Enforcement Administration (DEA) published a Final Rule moving hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II. This Final Rule imposes the regulatory controls and sanctions applicable to Schedule II substances on those who handle or propose to handle HCPs. The rule goes into effect 45 days from its publish date.
More Latest News
May 23, 2016
Executive Director Allison Dudley, Board Chair Debra Glass, Board Vice Chair Mark Mikhael and Board members Jeffrey Mesaros and Jeenu Philip attended… Continue reading
April 8, 2016
FDA MedWatch – Opioid Pain Medicines: Drug Safety Communication – New Safety Warnings Added to Prescription Opioid Medications ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication … Continue reading